Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment
Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 18 days
Novo Nordisk and Hims bury the hatchet and carve a deal (2 days)
Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (8 days)
GLP‑1 drugs associated with lower addiction risk in large study (10 days)
HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)
Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.